ANTIENDOTHELIAL ANTIBODIES IN THE SERA OF CANCER-PATIENTS - A POSSIBLE INDICATOR OF TREATMENT-INDUCED TISSUE-DAMAGE

被引:0
|
作者
KUMAR, S [1 ]
CAIRNDUFF, F [1 ]
WANG, M [1 ]
PYE, D [1 ]
KUMAR, P [1 ]
ALLAN, E [1 ]
HUNTER, RD [1 ]
机构
[1] MANCHESTER POLYTECH, MANCHESTER M20 9BX, ENGLAND
来源
CANCER JOURNAL - FRANCE | 1992年 / 5卷 / 05期
关键词
ANTIENDOTHELIAL ANTIBODY; RADIOTHERAPY AND AUTOANTIBODY; CHEMOTHERAPY AND AUTOANTIBODY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background - Radiation can cause severe injury to the vasculature in patients receiving radiotherapy. However, no assay is available which can either detect or predict such damage. In several diseases where damage to the vasculature occurs, the presence of antibodies to endothelial cells (AEA) has been noted. Methods - The incidence of AEA in the sera of normal individuals and cancer patients who have been treated by radiotherapy, chemotherapy, or radiotherapy and chemotherapy in combination, was investigated by an indirect immunofluorescence technique against human umbilical vein endothelial cells. Results - The incidence of AEA in the sera of 57 untreated cancer patients and 147 normal individuals was significantly lower than in 277 treated cancer patients (p=0.001, Pearson's Chi-squared test). The incidence of AEA was higher in cancer patients with disseminated disease than in patients with localised disease. Furthermore, 8/28 patients with AEA but only 20/242 without AEA, died during the course of this study (p=0.01, Pearson's Chi-squared test). Discussion - The higher incidence of AEA in the sera of treated cancer patients was predictable. To assess the clinical usefulness of these findings, longer-term follow-up studies need to be undertaken.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 50 条
  • [21] AN IMMUNOCHEMICAL ASSAY FOR NATURAL IGM ANTIBODIES WITH AN AFFINITY TO GALACTOSE AND WHOSE TITER IS REDUCED IN THE SERA OF CANCER-PATIENTS
    GROSS, DJ
    SIMON, E
    SZWARCBILOTYNSKI, L
    MARGALIOTH, E
    GROSS, J
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (03): : 363 - 367
  • [22] ANTI-POLY(A) POLYMERASE ANTIBODIES IN SERA OF TUMOR-BEARING RATS AND HUMAN CANCER-PATIENTS
    STETLER, DA
    ROSE, KM
    JACOB, ST
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (12): : 7732 - 7736
  • [23] NOVEL BIOMARKERS OF TREATMENT-INDUCED MUSCLE DAMAGE, CANCER-RELATED FATIGUE AND EXERCISE: AN RCT IN 90 BREAST CANCER PATIENTS
    Mustian, Karen M.
    Lin, Po-Ju
    Culakova, Eva
    Colasurdo, Ann
    Dunne, Richard F.
    Fung, Chunkit
    Gilmore, Nikesha J.
    Heckler, Charles E.
    Inglis, Julia E.
    Janelsins, Michelle C.
    Kamen, Charles
    Kleckner, Amber S.
    Kleckner, Ian
    Loh, Melissa
    Lopez, Gilberto
    Peppone, Luke J.
    Porto, Michelle
    Ramsdale, Erika
    Morrow, Gary R.
    ANNALS OF BEHAVIORAL MEDICINE, 2020, 54 : S709 - S709
  • [24] Optimal Management of Cancer Treatment-Induced Bone LossConsiderations for Elderly Patients
    Karen Tipples
    Anne Robinson
    Drugs & Aging, 2011, 28 : 867 - 883
  • [25] CORYNEBACTERIUM-PARVUM - ANTIBODIES MEASURED WITH THE ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA) IN NORMAL HUMAN-SERA AND SERA FROM CANCER-PATIENTS UNDERGOING TREATMENT
    RUITENBERG, EJ
    BUYS, J
    URSEM, PS
    ANNALES D IMMUNOLOGIE, 1982, D133 (03): : 305 - 311
  • [26] Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer
    Michaud, Laura Boehnke
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (07) : S20 - S30
  • [27] Orthopaedic management for cancer treatment-induced bone loss in postmenopausal breast cancer patients
    Tsujino, S.
    Koyanagi, H.
    Sawamura, C.
    Matsumoto, H.
    Inoue, K.
    Yoshii, T.
    Gokita, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1393 - S1394
  • [28] Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer
    Shunji Takahashi
    Journal of Bone and Mineral Metabolism, 2023, 41 : 307 - 316
  • [29] DEVELOPMENT OF NORMAL TISSUE-DAMAGE IN THE RAT SUBSEQUENT TO THORACIC IRRADIATION AND PRIOR TREATMENT WITH CANCER CHEMOTHERAPEUTIC-AGENTS
    MANSFIELD, CM
    KIMLER, BF
    HENDERSON, SD
    SVOBODA, DJ
    VATS, TS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (05): : 425 - 430
  • [30] Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer
    Takahashi, Shunji
    JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (03) : 307 - 316